Desq Long
Sign in

Company

Spyre Therapeutics, Inc.

SYRE · CIK 0001636282

SEC FORM 4
$1,629,029.20

Spyre Therapeutics, Inc. (SYRE)

Sale of 18,232 shares at $89.35 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$5,800.00

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 400 shares at $14.50 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code M

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$36,000.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 400 shares at $90 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$215,900.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,500 shares at $86.36 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$732,060.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 8,400 shares at $87.15 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$325,822.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 3,700 shares at $88.06 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$35,628.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 400 shares at $89.07 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$108,750.00

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 7,500 shares at $14.50 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$77,625.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 900 shares at $86.25 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$381,890.24

Spyre Therapeutics, Inc. (SYRE)

Sale of 4,384 shares at $87.11 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$177,468.48

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,016 shares at $88.03 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$17,808.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 200 shares at $89.04 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$405,985.50

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 27,999 shares at $14.50 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$418,608.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 4,845 shares at $86.40 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$1,442,985.60

Spyre Therapeutics, Inc. (SYRE)

Sale of 16,548 shares at $87.20 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$547,183.02

Spyre Therapeutics, Inc. (SYRE)

Sale of 6,206 shares at $88.17 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$35,752.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 400 shares at $89.38 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →